Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Romanian Journal of Internal Medicine
Volume 60 (2022): Issue 1 (March 2022)
Open Access
Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome
Hasan H. Yeter
Hasan H. Yeter
,
Ulver Derici
Ulver Derici
,
Turgay Arinsoy
Turgay Arinsoy
,
Kadriye Altok
Kadriye Altok
,
Yasemin Erten
Yasemin Erten
and
Galip Guz
Galip Guz
| Mar 17, 2022
Romanian Journal of Internal Medicine
Volume 60 (2022): Issue 1 (March 2022)
About this article
Previous Article
Next Article
Abstract
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Published Online:
Mar 17, 2022
Page range:
56 - 65
Received:
Jun 22, 2021
DOI:
https://doi.org/10.2478/rjim-2021-0034
Keywords
atypical hemolytic uremic syndrome
,
eculizumab
,
therapeutic plasma exchange
,
discontinuation
,
prognosis
© 2022 Hasan H. Yeter et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.